Clearside Biomedical, Inc. (CLSD) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
900 North Point Parkway
Alpharetta, GA 30005
United States of America (the)
Phone
678 270 3631
Website
Sector
Healthcare
Industry
Biotechnology
Employees
32
First IPO Date
June 02, 2016
| Name | Title | Pay | Year Born |
| Charles A. Deignan | Principal Financial Officer & Principal Accounting Officer | 576,488 | 1964 |
| George Lasezkay | Director & Principal Executive Officer | 853,085 | 1952 |
| Rafael V. Andino | Senior Vice President of Engineering & Manufacturing | 0 | 1965 |
| Rick McElheny | Senior Vice President of Corporate Development & Alliance Management | 0 | N/A |
| Jenny R. Kobin | Head of Investor Relations | 0 | 1967 |
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to pioneering novel drug delivery methods to the posterior segment of the eye via the suprachoroidal space. Its commercial product, XIPERE, is a triamcinolone acetonide suprachoroidal injectable suspension designed for treating uveitis macular edema. The company's development pipeline also features CLS-AX, an axitinib injectable suspension administered into the suprachoroidal space, which is currently undergoing Phase 1/2a clinical trials. Additionally, they are advancing CLS-301, an integrin inhibitor suspension aimed at addressing diabetic macular edema and macular degeneration. Clearside maintains strategic partnerships with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Established in 2011, Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.